SeaStar Medical Holding Corp (NAS:ICU)

Q1 2026 SeaStar Medical Holding Corp Earnings Call Transcript

May 13, 2026 / 08:30 PM GMT

Release Date Price: $4.6 (-4.96%)

Transcript 10-Q8-K

Key Points

Positve

SeaStar Medical Holding Corp (ICU) reported a 69% increase in Quelimmune net revenue for Q1 2026 compared to Q1 2025.
The company added seven new hospitals to its Quelimmune customer base in Q1 2026, with a goal of 15 new customers for the year.
SeaStar Medical is making significant progress in its NEUTRALIZE-AKI pivotal trial, with 198 out of 339 planned patients enrolled.
The company is working closely with the FDA on a modular PMA submission and rapid approval pathways for its SCD therapy.
SeaStar Medical maintains a strong financial discipline, with a gross profit margin of over 90% and cash reserves of $9.3 million as of March 31, 2026.

Negative

The company reported a net loss of approximately $3.5 million for Q1 2026, although this is an improvement from the previous year.
Operating expenses remained unchanged at $4.1 million, indicating ongoing high costs.
The completion of the NEUTRALIZE-AKI trial enrollment is not expected until the end of 2026, delaying potential market entry.
The transition of the SAVE registry from mandatory to voluntary status is pending FDA approval, which could impact adoption rates.
Integration of the SCD therapy into ICU workflows is described as 'non-trivial,' suggesting potential challenges in hospital adoption.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ICU.OQ - SeaStar Medical Holding Corp
Q1 2026 SeaStar Medical Holding Corp Earnings Call
May 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and welcome to the CSTAR Medical First Quarter 2026 Financial Results Conference Call.

At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask the question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised.

To withdraw your question, please press *11 again.

I would now like to hand the conference over to Jackie Coffman. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.